Table 3.
Registered Ongoing Clinical Trials (https://Clinicaltrials.gov/) of Small-molecule Chemical Radiosensitizers
Identifier | Drugs | Conditions | Phase | Initiation |
---|---|---|---|---|
NCT02363829 | Nelfinavir | Uterine cervix cancer | I | February 2015 |
NCT02459457 | Paclitaxel | Stage III esophageal squamous cell carcinoma | III | July 2015 |
NCT02598687 | TH-302 | Esophageal cancer | I | December 2015 |
NCT02724618 | Curcumin | Prostate cancer | II | March 2016 |
NCT03066154 | Docetaxel | Prostatic neoplasms | I | September 2016 |
NCT02757651 | Hydrogen peroxide | Breast cancer | I/II | January 2017 |
NCT02871843 | RRx-001 | Glioblastoma | I | February 2017 |
NCT03101995 | Gemcitabine | Cervical cancer | II | July 2017 |
NCT03824327 | Papaverine Hydrochloride | Lung non-small-cell carcinoma | I | February 2019 |